Exploiting this feature, several low-molecular-weight Glu-ureido–based PSMA inhibitor radioligands for Positron Emission Tomography/Computed Tomography (PET/CT) have entered the clinical scope of PC workup [4–6]. The gene discussed is FOLH1; the disease is pachyonychia congenita.